BGI Group signed three Memorandum of Understandings (MOUs) in the lead up to the G20 Summit in Bali with the Indonesian Ministry of Health, the University of Indonesia and the Del Institute of Technology (Institut Teknologi Del). The MOUs cover genomics development initiatives, construction of related laboratories, and joint research and personnel training.
Coordinating Minister of Maritime and Investment Affairs of Indonesia, Luhut Binsar Pandjaitan (third from left), Indonesian Minister of Health, Budi Gunadi Sadikin (first from left), and Chairman and Co-Founder of BGI Group, Wang Jian (second from left) witnessed the signing of the MOU between the Indonesian Ministry of Health and BGI Group
The signings were witnessed by Coordinating Minister of Maritime and Investment Affairs of Indonesia, Luhut Binsar Pandjaitan, Indonesian Minister of Health, Budi Gunadi Sadikin, and Chairman and Co-Founder of BGI Group, Wang Jian.
Indonesian Minister of Health, Budi Gunadi Sadikin, holds discussions with Chairman and Co-Founder of BGI Group, Wang Jian
Wang Jian also spoke during the "Tri Hita Karana (THK) Future Knowledge Summit" in Bali, an official side event of the G20 Summit, on “DNA Cell STOmics For All In The Emerging Future”.
Chairman and Co-Founder of BGI Group, Wang Jian, delivers his speech on "DNA Cell Stomics For All In The Emerging Future"
Genomics was announced as an integral part of the Indonesian Ministry of Health's medical transformation strategy. On August 14th, 2022, Indonesia established its first national integrated biomedical program, the "Biomedical and Genome Science Initiative" (BGSi). MGI was selected as one of the technology providers for the first phase of its effort towards establishing an accountable, accurate, and credible population database of 10,000 whole genomes. MGI, with the help of its strategic local partner PT Bakti Energi Abadi, will create a total workflow based on ultra-high-throughput genetic sequencer DNBSEQ-T7RS*, the MGISP-960RS and MGISP-NE384RS automation systems, and ZTRON data platform.
MGI's DNBSEQ™ sequencing platform can meet the needs of ultra-high throughput sequencing, and low cost with fully automation from sample to report. It will make gene sequencing technology accessible for more people, promote the development of precision medicine, and accelerate the progress of the human genome era.
With the goal of providing our global customers with "the right to another choice", MGI is mission-oriented to develop and promote advanced life science tools for future healthcare to empower human health, contributing to building a "community with a shared future for mankind".
*For StandardMPS and CoolMPS: Unless otherwise informed, StandardMPS and CoolMPS sequencing reagents, and sequencers for use with such reagents are not available in Germany, Spain, UK, Sweden, Belgium, Italy, Finland, Czech Republic, Switzerland, Portugal, Austria and Romania. Unless otherwise informed, StandardMPS sequencing reagents, and sequencers for use with such reagents are not available in Hong Kong. No purchase orders for StandardMPS products will be accepted in the USA until after January 1, 2023.